Skip to main content

Polyrizon Ltd.

corporate_fare Company Profile

Polyrizon Ltd.

PLRZ·NASDAQ·Industrial Applications And Services·CIK 0001893645

Polyrizon Ltd. is a development stage biotech company incorporated in Israel in January 2005. The company specializes in developing innovative medical device hydrogels delivered as nasal sprays. These hydrogels form a thin, shield-like containment barrier in the nasal cavity, designed to protect against viruses and allergens contacting the nasal epithelial tissue. Polyrizon's C&C hydrogel technology uses a mixture of naturally occurring building blocks and is delivered via nasal sprays, potentially acting as a "biological mask." The company is also developing aspects of its C&C hydrogel technology, including bioadhesion and prolonged retention at the nasal deposition site, for the intranasal delivery of drugs. This separate platform technology, focused on nasal delivery of Active Pharmaceutical Ingredients (APIs), is referred to as T&T. Polyrizon's principal executive offices are located at 8 HaPnina Street, Raanana, 4321545, Israel. Their telephone number in Israel is +972-9-3740120.

Polyrizon Ltd. (NASDAQ:PLRZ) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors PLRZ SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Polyrizon Partners with Clearmind Medicine to Develop Intranasal Neuroplastogen Formulation
  • Polyrizon to Acquire 51% Stake in Private Aviation Company, Pivoting from Biotech
  • Polyrizon Begins Key Usability Study for NASARIX™ Allergy Blocker, Advancing FDA Path
  • Polyrizon's PL-14 Allergy Blocker Shows Significant Pre-Clinical Efficacy Against Allergens

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$3.33M
Diluted EPS
$4.90
Op. Cash Flow
-$4.53M
Free Cash Flow
-$4.54M
Operating Income
-$6.25M
Cash & Equivalents
$1.31M
Debt / Equity
0.00×
Shares Outstanding
1.61M sh
Source: 20-F · filed 2026-03-27 · accession 0001213900-26-035204

Insider Transactions

PLRZ files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$11.13
52-week range · as of 2026-06-10 $2.88 – $18.2
Market cap
$19.84M
Volume
27.4K (0.8× avg)
3-mo avg 35.7K
Live data · 2026-06-14 05:12 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PLRZ - Filings & News (Page 2)

PLRZ
Feb 06, 2026, 7:58 AM EST
Filing Type: 6-K
Importance Score:
7
Polyrizon Partners with Clearmind Medicine to Develop Intranasal Neuroplastogen Formulation
Price at Filing: $13.05
Real-time Price: $11.13 info
Change: -$1.92 (-15%) info
Market Cap: $19.843M info
Sentiment: Positive
View Wiseek Article
PLRZ
Feb 04, 2026, 7:13 AM EST
Filing Type: 6-K
Importance Score:
9
Polyrizon to Acquire 51% Stake in Private Aviation Company, Pivoting from Biotech
Price at Filing: $17.50
Real-time Price: $11.13 info
Change: -$6.37 (-36%) info
Market Cap: $19.843M info
Sentiment: Neutral
View Wiseek Article
PLRZ
Jan 22, 2026, 9:28 AM EST
Filing Type: 6-K
Importance Score:
7
Polyrizon Begins Key Usability Study for NASARIX™ Allergy Blocker, Advancing FDA Path
Price at Filing: $16.19
Real-time Price: $11.13 info
Change: -$5.06 (-31%) info
Market Cap: $19.843M info
Sentiment: Positive
View Wiseek Article
PLRZ
Jan 05, 2026, 9:10 AM EST
Filing Type: 6-K
Importance Score:
8
Polyrizon's PL-14 Allergy Blocker Shows Significant Pre-Clinical Efficacy Against Allergens
Price at Filing: $12.00
Real-time Price: $11.13 info
Change: -$0.870 (-7%) info
Market Cap: $19.843M info
Sentiment: Positive
View Wiseek Article